Was your holiday meal noticeably lighter this season? Fewer roasted potatoes? Absent Brussels sprouts? Tiny Yorkshire puddings?
The reason might be GLP-1, commonly recognized as weight-loss injections like Ozempic or Mounjaro.
Weight-loss injections such as Ozempic have altered festive meal preparations for many Brits. Recent studies show changes in buying habits and rising concerns among hosts. Health tracking tools can aid in monitoring these shifts.
Was your holiday meal noticeably lighter this season? Fewer roasted potatoes? Absent Brussels sprouts? Tiny Yorkshire puddings?
The reason might be GLP-1, commonly recognized as weight-loss injections like Ozempic or Mounjaro.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Recent information indicates that 60% of UK residents on weight-loss jabs modified their Christmas dinner shopping patterns prior to the holiday, opting for fewer groceries.
And it's not solely those on the injections affected; CheqUp's data demonstrates over half of British hosts for Christmas dinner experiencing worry regarding the appropriate portion sizes for their holiday meal. Health tracking apps like Shotlee can help monitor diet and weight loss progress.
Original source: LBC
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.